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Abstract
Melanoma treatment depends largely on the clinical stage of the disease. The preferred 
treatment is surgical resection of the disease. The surgical margins depend on the depth 
of the disease. Sentinel lymph node biopsy is generally advised for all lesions greater than 
1 mm depth. Complete lymphadenopathy of surrounding lymph nodes is recommended 
in the presence of nodal disease. There are some controversies surrounding the timing 
and benefit of complete lymphadenopathy in clinically occult disease. There is evidence 
to support the role of adjuvant therapies in the form of immunotherapy in regionally 
advanced disease, and there has been a significant improvement in medical therapies 
for advanced melanoma. BRAF inhibitors have become mainstay treatment for patients 
with a BRAF mutation. Immunotherapy is another cornerstone of therapy for advanced 
melanoma. There is ongoing research to define the optimal therapeutic regimen. Future 
guidelines will likely incorporate this recent research. Chemotherapy has been relegated 
to second-line therapy in melanoma.
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1. Introduction
Melanoma is the deadliest of all the skin cancers. The incidence has been increasing in 
recent decades. There has been a significant development of therapies for melanoma. For 
the purpose of chapter, the staging of melanoma will be reviewed. There will be a brief over-
view of the current recommendations and ongoing research into the different therapeutic 
approaches. 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the t rms of the Crea ive
Comm ns Attribution Lic nse (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. Determining the appropriate therapy
An important determinant of the appropriate treatment strategy is the clinical stage of the pri-
mary melanoma. Melanoma is staged by the TNM system. T refers to the primary tumour, N 
refers to the nodal status and M refers to the metastatic status. The AJCC released updated 
guidelines for the staging of melanoma in 2016. T1a tumours are less than 0.8 mm deep without 
ulceration, and T1b tumours are either less than 0.8 mm deep with ulceration or 0.8 mm to 1 mm 
deep with or without ulceration. T2a and T2b tumours are 1.0 mm to 2.0 mm without and with 
ulceration, respectively. T3a and T3b tumours are 2.0 mm to 4.0 mm without and with ulceration, 
respectively. Finally, T4a and T4b tumours are greater than 4.0 mm without and with ulceration, 
respectively. N1 refers to one-tumour involved or any number of in-transit satellite and/or mic-
rosatellite metastases with no tumour-involved lymph node. N1a and 1b refer to one clinically 
occult (detected by SLNB) and one clinically detected. N2 refers to two or three tumour-involved 
nodes or any number of in-transit, satellite, and/or microsatellite metastases with one tumour-
involved node. N2a and N2b refer to two or three clinically occult and at least one clinically and 
one clinically occult/clinically detected, respectively. N3 refers to four or more tumour-involved 
nodes or any number of in-transit, satellite, and/or microsatellite metastases with two or more 
tumour-involved nodes or any number of matted noes without or with in-transit, satellite and/or 
microsatellite metastases. N3a, N3b and N3c refer to four or more clinically occult, four or more, 
at least one of which was clinically detected or the presence of any number or matted nodes or 
two or more clinically occult or clinically detected and/or the presence of any number of matted 
nodes, respectively. Satellite metastases are clinically apparent cutaneous and/or subcutaneous 
metastases within 2 cm of the tumour. Microsatellites are microscopic cutaneous and/or subcu-
taneous metastases next to or below the melanoma on histological examination. In-transit metas-
tases are clinically apparent cutaneous and/or subcutaneous metastases found greater than 2 cm 
from the primary melanoma. M0 refers to no distant disease, and M1 refers to distant disease. 
M1a refers to distant metastases in the skin, soft tissue including muscle, M1b refers to distant 
metastasis to lung, M1c refers to distant metastasis to non-CNS visceral sites and M1d refers to 
distant metastasis to the CNS. M can be further risk stratified based on the LDH level [1].
Stage 1 and 2 are defined by tumour size. Stage 3 is defined by positive nodal disease. Stage 4 is 
defined by the presence of metastases. Based on the TNM staging, stage 0 refers to T1sNoMo, 
stage 1a refers to T1a/N0/M0, stage 1b refers to T1b or T2a/N0/M0, stage 2A refers to T2b or 
T3a/N0/M0, stage 2B refers to T3B or T4a/N0/M0, stage 2C refers to T4b/N0/M0, stage 3 refers 
to any T/N1 or higher/M0 and stage 4 refers to any T/any N/M1 [1].
2.1. Stages 0, 1 and 2
The ESMO guidelines recommend surgical therapy as the primary management strategy 
in localised melanoma. The guideline recommends against performing routine lymphadenec-
tomy or irradiation to the surrounding lymph nodes. The guideline recommends radiother-
apy for local disease control where there are positive margins in lentigo maligna melanoma, 
in cases of metastases resection where there are positive histological margins or after the 
removal of bulky disease [2].
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2.1.1. Surgical
Surgical excision forms the cornerstone of treatment in primary cutaneous melanoma. 
Following the initial histological diagnosis and microstaging of the tumour, a wider and 
often deeper excision of the melanoma is performed. The surgical management of melanoma 
depends primarily on the Breslow thickness, the presence or absence of ulceration, and posi-
tivity of sentinel lymph node biopsy [3]. The ultimate aim of surgical therapy irrespective of 
depth is to obtain clear margins. The extent of the surgical margins is determined by three 
factors: (1) Wide margins result in a reduced risk of local recurrence. (2) There is no benefit 
to excising margins beyond 1 cm in thin melanoma. (3) There is no demonstrated benefit to 
excising margins beyond 2 cm in any thickness melanoma. The guidelines suggest a margin 
between 1 cm and 2 cm for primary cutaneous melanoma. Furthermore, the guidelines state 
that an excision should be performed to the level of muscle fascia or depending on tumour 
location at least to the level of the deep adipose tissue. However, in the case of stage 0 mela-
noma, an excision margin between 0.5 and 1.0 cm margin is acceptable. In the case of stage 
0 lentigo maligna, margins may need to be extended to >0.5 cm, due to characteristically 
widespread subclinical extension. Permanent section total peripheral margin control and 
Moh’s micrographic surgery have been used to achieve histological control of the margins. 
However, there is a paucity of evidence to support their use [4].
There are several trials performed to determine the optimal extent of the margins when excis-
ing melanoma. In thin melanomas, an international, randomised prospective study examined 
1 cm margins in the context of primary cutaneous melanomas less than 2 mm depth. A total 
of 612 patients were included in the trial, with 305 randomised to 1 cm margins and 307 ran-
domised to wide margins less than 3 cm. The disease-free and overall survival was similar in 
the two groups [5]. In the case of intermediate-thickness tumours (1 to 4 mm depth), a large, 
multicentre randomised trial demonstrated that margins of 2 cm were acceptable with respect 
to 5-year survival. Reducing the margins from 4 to 2 cm led to a significant reduction in skin 
grafting and total length of hospital stay [6]. In another multicentre trial, they investigated the 
optimal excision margins in high-risk melanoma. High-risk melanoma was defined as localised 
melanoma 2 mm or greater in thickness on the trunk or limbs. Elective lymph-node dissection, 
sentinel biopsy and adjuvant therapies were not permitted. Patients were either randomised 
to 1 cm or 3 cm margins. The trial demonstrated that a 1 cm margin in high-risk melanoma is 
associated with a significant increase in regional recurrence vs. a 3 cm margin, but both patient 
populations had a similar overall survival rate [3]. A Cochrane review examined the different 
excision margins in melanoma. A narrow margin was defined as 1–2 cm, and a wide margin 
was defined as 3–5 cm. The systematic review included data from randomised trials for 1633 
participants in the narrow excision margin group and 1664 in the wide excision margin group. 
There was no statistically significant difference in terms of overall survival and recurrence free 
survival between wide and narrow margins. However, there was a trend toward improved 
overall survival and recurrence free survival. The review concluded that there was inadequate 
evidence to determine the optimal excision margins for primary cutaneous melanoma [7].
Sentinel lymph node biopsy should be considered in patients with a primary cutaneous mel-
anoma of 1 mm or greater depth. Sentinel lymph node biopsy is generally not advised in 
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patients with stage 0 or stage 1a melanoma. The use of sentinel lymph node biopsy is only rec-
ommended in stage 1B in the presence of adverse prognostic indictors [4]. The likelihood of 
a positive sentinel lymph node biopsy increases with the Breslow’s depth, with 2% in 1 mm, 
7% in 1–1.99 mm, 13% in 1–1.99 mm, and 31% in 3 mm. In 710 cases of sentinel lymph node 
biopsy, 638 (88.5%) were alive without evidence of disease [8].
Lymph node dissection plays an important role in the surgical management of melanoma. 
The MSLT-1 was a multicentre phase 3 trial, which randomised two groups of patients with 
localised melanoma more than 1 mm deep to receive either wide excision with lymphatic 
mapping and sentinel lymph node biopsy with immediate complete lymphadenectomy for 
sentinel node metastases or wide excision plus postoperative observation with a deferral of 
the complete lymphadenectomy until clinically evident disease became apparent. The trial 
comprised of 1270 patients with intermediate-thickness melanoma, 290 with thick melanoma, 
and 232 with thin melanoma. There was no difference between the immediate and delayed 
complete lymphadenectomy group in the absence of nodal disease in either the intermediate 
or thick melanomas group with respect to 10-year melanoma-specific survival rates. The sur-
vival rate was much improved in the presence of nodal disease in the biopsy vs. observation 
group in the intermediate thickness group. However, a similar benefit was not observed in the 
thick melanoma group. The patients with a positive sentinel lymph node biopsy had a worse 
prognosis vs. the patients with negative sentinel lymph node biopsy. Thus, there is a clear 
benefit to immediately complete lymphadenectomy following the identification of clinically 
occult disease in intermediate-thickness melanoma with respect to nodal recurrence, distant 
metastases and melanoma-specific survival. The timing of the complete lymphadenectomy 
does not appear to play an important role in thick melanomas. There is no benefit to immedi-
ate complete lymphadenectomy in the absence of clinically occult disease. Finally, the trial 
demonstrates that sentinel lymph node biopsy serves as an important prognostic tool [9].
Another important trial which assessed the role of complete lymph node dissection was the 
phase 3, multicentre, DeCOG-SLT trial. They examined whether complete lymph node dis-
section results in a better overall survival vs. conservative management in patients with posi-
tive sentinel lymph node biopsies. The patients had cutaneous melanoma of at least 1 mm 
depth and positive sentinel lymph node biopsies. The trial randomised 483 patients to either 
complete lymph node dissection or observation. There was no significant difference in terms 
of distant-metastasis free survival in the treatment or observation arm (74.9% vs. 77.0%). 
Furthermore, there was no significant difference in terms of 3 year overall survival between 
the treatment and observation arm (81.2% vs. 81.7%). There was only a small improvement in 
disease control in the treatment vs. the observation group 8% vs. 15%). It is important to note 
that the majority of patients in that study had a low tumour burden [10].
2.1.2. Non-surgical
Surgical management is the treatment of choice for primary cutaneous melanoma. Hence, the 
non-surgical options should only be advised in specific cases, where surgery is not possible. 
The options include topical imiquimod, radiation therapy, cryosurgery and observation [4].
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2.2. Stage 3
The ESMO guidelines suggest surgical excision and removal of the surrounding lymph nodes. 
They note that it is not sufficient to merely remove the disease-containing nodes. These guide-
lines define high-risk situations as the presence of multiple bulky lymph node metastases. 
The surgical management of stage III melanoma follows the same principles as above. The 
guidelines suggest the consideration of localised radiation therapy to the surrounding area in 
the case of high-risk disease. In the presence of inoperable, regionally advanced disease, the 
guidelines suggest therapies such as isolated limb perfusion, radiation therapy, electroche-
motherapy or intralesional therapy [2].
In the presence of high-risk disease, systemic therapy should be considered. A recent phase 
3 trial investigated the role of adjuvant immunotherapy in high risk regionally advanced to 
prevent recurrence. The trial entitled EORTC 18071 enrolled participants who underwent a 
surgical excision of cutaneous melanoma with clear margins. A total of 951 patients were 
randomly assigned to the treatment with either placebo or ipilimumab. The median recur-
rence survival was significantly improved in the ipilimumab treatment arm (26.1 months vs. 
17.1 months). There were a large number of patients who discontinued ipilimumab due to 
adverse events (245/471). These adverse events were most commonly GI (75/472), hepatic 
(50/472), and endocrine (40/471). There were five treatment-related deaths in the ipilimumab 
treatment arm (three due to colitis, one due to myocarditis and one due to Guillain-Barré syn-
drome) [11]. The overall 5-year survival in the ipilimumab treatment arm at 5 years was 65.4% 
vs. 54.4% in the placebo arm [12].
However, the role of ipilimumab as the optimal adjuvant therapy has recently been chal-
lenged with the publication of a phase 3 trial, comparing adjuvant nivolumab vs. ipilimumab 
in resected stage 3 or 4 melanoma. A total of 906 patients were randomly assigned to either 
receive treatment with ipilimumab or nivolumab. The patients were followed up for at least 
18 months. When the 12-month recurrence-free survival was compared in both groups, it 
was significantly higher in the nivolumab group (70.5% vs. 60.8% respectively). Nivolumab 
appeared to have a better overall side-effect profile, with 14.4% reporting grade 3 or 4 adverse 
treatment effects vs. 45.9% in the ipilimumab-treatment arm. Furthermore, while there were 
two deaths reported in the ipilimumab arm, there were no deaths recorded in the nivolumab 
arm [13].
A recent phase 3 trial published in 2017 suggests that the BRAF inhibitor dabrafenib plus 
the MEK inhibitor trametinib prove the optimal treatment option in stage III melanoma 
patients with the BRAF V600 mutations. A more detailed discussion regarding the mecha-
nism of these drugs will be discussed in the stage IV section. They randomised patients 
with either a BRAF V600E or V600 K mutation to receive either a combination of dabrafenib 
and trametinib or placebo. They recruited 870 patients with adequately resected stage 3 
melanoma. The overall 3-year survival was improved in the treatment arm vs. placebo (86% 
vs. 77%). The 3-year relapse free survival was 58% vs. 39% in the treatment vs. placebo 
arm, respectively. This trial suggests a role for combination BRAF/MEK therapy in stage 3 
melanoma [14].
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In conclusion, surgery with removal of surrounding lymph nodes remains the mainstay therapy 
for stage III disease. Several recent publications suggest a benefit to systemic therapy with check-
point inhibitors or BRAF inhibitors if applicable in high-risk disease. Future guidelines will likely 
incorporate this recent research into their treatment strategies for regionally advanced disease.
2.3. Stage 4
The most significant breakthrough in melanoma in recent years has included the therapies 
designed for metastatic malignant melanoma. The main determinant of treatment strategy 
is the presence of resectable or unresectable disease. In the presence of resectable disease, 
the disease may be managed as the above. In the case of unresectable disease, the ESMO 
guidelines note that the optimal 1st-line therapy in melanoma remains under considerable 
debate. They suggest either anti-PD1 therapies or BRAFi/MEKi for BRAF-mutated melano-
mas. Chemotherapy has been relegated to 2nd-line therapy in the guidelines. However, in 
the case of aggressive metastatic disease, the guidelines note some benefit to polypharmacy, 
containing paclitaxel and carboplatin/cisplatin, vindesine, and dacarbazine [2]. Furthermore, 
radiation therapy is recommended in the presence of symptomatic brain metastases or pain-
ful bony metastases. However, the guidelines will likely evolve dramatically following the 
development of further therapeutic strategies.
2.3.1. MAPK pathway inhibitors
Dysregulation of the RAS/RAF/MEK/ERK MAPK pathway plays a pivotal role in the devel-
opment of MM. In healthy cells, this pathway regulates several physiological cellular pro-
cesses. The MAPK pathway is activated by growth factors which bind to the extracellular 
kinase receptor. This receptor-ligand complex leads to autophosphorylation of intracellular 
domains, which in turn results in phosphorylation and activation of the membrane-bound gua-
nosine triphosphatase RAS. There is dimerisation of the serine/threonine kinases RAF. RAF 
is encoded by three different isoforms: ARAF, BRAF, and CRAF. The BRAF isoform encodes 
for the most powerful activator of the MAPK pathway. Activation of RAF causes a phos-
phorylation cascade, with the eventual activation of ERK. ERK is then free to translocate to 
the nucleus, where it activates several transcription factors that induce the expression of genes 
implicated in normal cell turnover and survival [15, 16].
In 2002, there was an exciting discovery that activating mutations in MAPK pathways play 
an essential role in most MM. A dysregulated MAPK pathway is present in ~40–50% of MM 
cases. The most common mutation resulting in dysregulation of the MAPK pathway is pres-
ent on exon 15 and results in the switching of glutamate for valine at codon 600 (V600E). 
This mutation is located within the activating segment of the kinase domain. The mutant 
form of BRAF is more potent than the wild type variant. The mutant form results in constitu-
tive activation of the MAPK pathway and increased ERK. The cellular endpoint is increased 
turnover and survival. The presence of BRAF mutations seems to be dictated by age; with 
80% of patients less than 30 years old harbouring a mutation, while only 20% of patients over 
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80 years old harbouring the mutation. Furthermore, older patients are less likely to have the 
V600E mutation. Finally, patients with the mutant BRAF had historically worse outcomes 
than the wild-type BRAF [16].
As a result of this new understanding of the underpinning genetic events that give rise to 
MM, there have been several drugs developed known as targeted therapy of the MAPK 
pathway. Initially, the broad spectrum tyrosine kinase, sorafenib, was trialled in melanoma 
patients [17]. The clinical trial results proved disappointing. There are two targeted thera-
pies subsequently developed and currently licenced, which inhibit mutated BRAF: vemu-
rafenib (formerly known as PLX4032) and dabrafenib. Vemurafenib was the first selective 
tyrosine kinase inhibitor licenced by the FDA in 2011. Dabrafenib is a potent and selective 
inhibitor of BRAF V600E kinase. Inhibition of the pathway may also be achieved by MEK 
inhibitors. Trametinib is a potent and selective inhibitor of MEK 1 and 2. These three MAPK 
targeted therapies are licenced by the US Food and Drink Authority for single-agent therapy 
against non-resectable or metastatic cutaneous MM. Combining MAPK pathway inhibitors 
is an important therapeutic strategy to minimise the development of drug resistance. There 
is an additional MEK inhibitor, known as cobimetinib licenced for combination therapy with 
vemurafenib. Similarly, dabrafenib and trametinib are licenced for combination therapy [18, 
19]. BVD-523 (ulixertinib), an ERK1/2 inhibitor with high potency and selectivity, is currently 
under investigation. Preclinical investigations in vivo and in vitro appear promising, and 
clinical trials are underway. This may prove an important combination therapy or refractory 
in future clinical practice [20].
An important therapeutic limitation is the development of resistance to the MAPK pathway 
inhibitors. The current literature suggests that progression-free survival for patients receiving 
BRAF/MEK inhibitor combinations ranges from 9 to 11 months [21–23]. The exact mechanism 
of resistance has not been fully elucidated, and there is ongoing research into the development 
of resistance. Several different mechanisms of resistance have been posed in the literature.
3. Immunotherapy
As seen in the previous section, melanoma is a highly mutated cancer. Similarly, it is extremely 
an immunogenic cancer. Attenuating the immune system has proved an important therapeu-
tic strategy. Immunotherapy targets 4 broad areas: (1) Checkpoint inhibitors. These agents 
negatively regulate inhibitors of pre-existing anti-tumour immune response (effectively aug-
menting the response of the immune system to the tumour cells, e.g., Anti-CTLA-4 inhibitors 
(ipilimumab), anti-PD-1/PD-L1 antibodies (nivolumab/pembrolizumab/atezolizumab) and 
IDO1 Inhibitors (Epacadostat); (2) Increasing the anti-tumour T cell response by administra-
tion of autologous ex-vivo augmented tumour infiltrating lymphocytes; (3) Administering 
oncolytic viruses into the metastatic cells to break-up the cells and increase the immune 
response and (4) Targeting dendritic cells to start and/or increase tumour antigen-specific 
immune responses [24].
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In order to appreciate the mechanism of the immunotherapies, it is necessary to briefly examine 
the normal physiology of the immune system. T cells are a subgroup of lymphocytes mainly 
produced in the thymus, which express antigen-recognising T-cell receptor (TCR). Every T-cell 
has a unique TCR, which recognises a specific antigen. Antigen is presented to the T-cell by the 
MHC complexes. This causes clonal expansion of T-cells. All progeny of a T-cell express the 
same TCR, and this expanded pool confers antigen-specific immunity. There are 4 main reasons 
why the T-cells are such a desirable target for immunotherapy: (1) The response to T-cell is spe-
cific, and differentiates between healthy and neoplastic cells; (2) T-cell responses are amplified, 
resulting in a 1000-fold increase in the response after activation; (3) T-cells travel to the specific 
area containing the antigen, enabling them to fight distant metastases; and (4) T-cells can remain 
quiescent, conferring immunity for many years after the initial exposure to antigen [25]. T cells 
may either be classed as effector T cells or T regulatory cells. Effector T-cells enable immunity 
and destroy cells with the particular antigen. T regulatory cells are essential for maintaining 
immunological unresponsiveness to self-antigen and preventing excessive immune responses 
harmful to the host. There are several different theories about how regulatory T-cells can attenu-
ate the immune response: 1. Secretion of immunosuppressive cytokines by regulatory T cells, 
cell-contact dependent inhibition, and modification/destruction of APC cells [26–28].
The key molecules required for the activation of both T cell types are similar. T cell activation is 
mediated by activation of the T-cell receptor and a co-stimulatory molecule, the CD28 receptor 
on the T cells by MHC peptides, and APC. Both are necessary for generation of an adequate 
immune response. Antigen is presented to the TCR, and a T-cell receptor complex including 
CD3, CD2, CD4/CD8/LFA1/CD45R is formed. This activation of TCR generates signal 1. CD28 
on T cells is activated by B7.1 and B7.2 on antigen-presenting cells, generating signal 2. B7.1 
and B7.2 are generally only expressed on specialised antigen presenting cells, e.g., dendritic 
and Langerhans. Cytotoxic T-cell associated antigen-4 (CTLA4) and glucocorticoid-induced 
TNF receptor (GITR) are expressed on T cells. CTLA4 combines with B7.1 and B7.2 and blocks 
activation of the CD28 molecules. CTLA4 has a greater affinity for B7.1 and B7.2 than CD28. 
CTLA4 sends a negative signal, downregulating expression of B7.1 and B7.2 [26–28].
3.1. Checkpoint inhibitors
Checkpoint inhibitors are based on the fact that T lymphocytes are essential for the antitu-
mour immunity. Furthermore, an antigen-specific TCR must be activated in the presence of 
co-stimulatory activation in order to activate the T-lymphocytes [29]. Several inhibitory recep-
tors and ligands present on T cells and tumour cells have been identified as potential tar-
gets for cancer immunotherapy. They are essential mediators of immune suppression in the 
tumour microenvironment [30]. They are different from monoclonal antibodies, which bind 
and destroy the tumour cells. Checkpoint inhibitors are immunomodulatory antibodies which 
either stimulate or inhibit the function of cell surface signalling molecules on the patient’s own 
immune cells. This can lead to either upregulation or downregulation of the patient’s immune 
cells [31]. Different negative co-stimulatory molecules exist. Targeting negative co-stimulatory 
molecules, such as CTLA4 and PD-1, is the basis of checkpoint inhibitors. The advantage of 
checkpoint inhibitors is that they function irrespective of the patients’ BRAF status [32].
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3.1.1. CTLA-4 inhibitors
CTLA-4 blocking antibodies prevent CTLA-4 from binding to its ligands B7-1 and B7-2 on 
APCs. This “unleashes the breaks” on the immune system. Experimental evidence sug-
gests that there is an increase in the absolute number of effector and regulatory T cells in the 
lymph nodes. However, there is an increase in the effector T cell to regulatory T cell ratio 
in the tumour microenvironment. Destruction of the regulatory T cells increases the ratio 
and directly correlated with rejection of the tumour. Another important mechanistic aspect 
of CTLA4 inhibitors is their effect on FcyR. FcyRs are responsible for the selective depletion 
of the regulatory T cells. FcyRs are key regulators of the immune response. FcyR is broadly 
expressed on cells of haemopoetic lineage, including B cells, macrophages, mast cells, NK cell 
and neutrophils. They can be both activating and inhibitory. Depletion of the T cells results 
from antibody-dependent cellular cytotoxicity, dependent on tumour-infiltrating CD11b-
positive macrophages expressing activating FcyRIV. CTLA4 stimulates activating FcyRIV, 
inducing the antibody-dependent cellular cytotoxicity. The depletion of regulatory T cells 
occurs preferentially in the tumour cells for several reasons. Macrophages are a lot more plen-
tiful in the tumour microenvironment (>50 times). Furthermore, there is a greater consump-
tion of the T regulatory cells due to the higher expression of CTLA4 on T regulatory cells vs. 
T effector cells. This ultimately leads to a higher effector T cell to regulatory T cell ratio in the 
tumour [31, 33].
In 2010, the CTLA4 inhibitor, ipilimumab, proved to improve overall survival in the ground-
breaking phase III clinical trials in patients with advanced melanoma. A total of 676 patients 
were included in the study with either stage III or IV melanoma. They randomised patients 
to receive ipilimumab, ipilimumab plus gp100, or gp100 alone (control group). The over-
all survival of patients who received ipilimumab vs. the control group was 10.0 months vs. 
6.4 months. There was no survival difference in overall survival in patients receiving ipili-
mumab vs. ipilimumab plus gp100. Ipilimumab alone resulted in the best overall response 
(10.9%) and disease control rate (28.5%). A total of 60% (n = 9/15) of patients receiving ipi-
limumab alone had a long-term response lasting more than 2 years. It is important to note 
that 10–15% of participants receiving ipilimumab suffered from grade 3 or 4 immune-related 
adverse events, most commonly relating to the skin and gastrointestinal system [34]. In clini-
cal trials, greater than 80% of participants experienced adverse events related to therapy with 
ipilimumab [35]. The most frequent severe immune-mediated adverse effects are enteroco-
litis, hepatitis, dermatitis (including TEN), neuropathy, and endocrinopathy. These adverse 
effects generally occur during treatment; however, they may occur in the weeks to months 
after ipilimumab discontinuation [35]. A pooled analysis was undertaken on the long-term 
survival data from phase II and III clinical trials, in patients with unresectable melanoma. The 
data included 1861 patients from 10 prospective and 2 retrospective trials. The median overall 
survival for patients receiving ipilimumab was 11.4 months. There were 254 patients with 
3-year survival follow-up. The 3-year survival rate was 22% [36].
When ipilimumab was combined with dacarbazine, the median duration of the best overall 
response was 19.3 months vs. 8.1 months in dacarbazine alone at long-term follow-up [30].
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EORTC 18071 was a multicentre phase 3 clinical trial with 951 patients comparing adjuvant 
ipilimumab (dose of 10 mg/kg) with placebo in resected, high-risk stage III melanoma. The 
overall survival rate at 5 years was significantly higher in the ipilimumab group vs. placebo 
(65.4% vs. 54.4%). The rate of distant metastasis-free survival at 5 years was increased in the 
ipilimumab vs. placebo (48.3% vs. 38.9%). 98.5% (n = 465/471) of patients receiving ipilimumab 
experienced an adverse event of any grade, and 26.2% experienced a grade 3 or 4 adverse 
event, with 41.6% of patients experiencing grade 3 or 4 immune-related adverse events in the 
ipilimumab group. The most common immune-related adverse events were GI, hepatic, and 
endocrine. Five patients (1.1%) died due to adverse events related to ipilimumab [12].
3.1.2. PD-1 inhibitors
The programmed death-1 (PD-1) is a regulatory molecule which is expressed on T cells and 
operates during the effector phase of T-cell activation. In contrast, CTLA-4 is operational 
during early activation of T cells in lymphatic tissues. PD-1 interacts predominantly with its 
two ligands, B7-H1 and B7-DC (PD-L1 and PD-L2) in peripheral tissues, and causes apop-
tosis and downregulation of T-cell effector function. The function of PD-1/PD-L1 interaction 
is to minimise the risk of surrounding tissue damage by T-cells. PD-1/PDL-1 therapies are 
considered “tumour site immune modulation therapy”. PD-L1 appears to be upregulated in 
the tumour microenvironment [30]. In order to extravasate peripheral tissues and organs, the 
T-cells must have encountered their antigen already in the lymphoid organs. T-cells primed 
with its antigen develop an immunologic memory and acquire a particular set of adhesion 
molecules that allow extravasation to the peripheral tissues, including the tumour. Once this 
T-cell encounters the antigen in the peripheral environment, PD-1 interacts with its ligands 
and thereby decreases the extent of the immune response. Therefore, PD-1 inhibitors tar-
get T-cells already engaged in the ongoing effector T-cell response and hence have a more 
restricted spectrum of T-cell activation compared with CTLA-3 blocking. This is probably the 
reason why there is a decreased rate of immune adverse events with anti-PD-1 or anti-PDL-1 
antibodies [30].
In 2015, a phase 3 multicentre clinical trial investigated 518 patients with BRAF-negative 
advanced stage III or IV melanoma randomised to either nivolumab (dose 3 mg/kg) or dacar-
bazine. At 1 year, the overall survival rate was 72.9% in the nivolumab group vs. 42.1% in the 
dacarbazine group. The median progression-free survival was 5.1 months in the nivolumab 
group vs. 2.2 months in the dacarbazine group. The objective response rate was 40% in 
the nivolumab group vs. 13.9% in the dacarbazine group. Therapy-related adverse effects 
occurred in 11.7% of the nivolumab group vs. 17.6% in the dacarbazine group. The most com-
mon effects included fatigue, pruritus, and nausea [37]. In another clinical trial, an analysis 
was performed on the safety data relating to nivolumab in both melanoma and other solid 
tumour groups (n = 306). Some patients were followed-up for safety monitoring over 2 years. 
The majority of adverse events occurred in the first 6 months of treatment. There were no 
cumulative toxicities with extended treatment periods [38].
In CHECKMATE 037, a phase-3 multicentre clinical trial, 631 patients with advanced mel-
anoma who progressed after CTLA-4 inhibitor were randomised to receive nivolumab or 
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 chemotherapy as second-line or later-line therapy. Confirmed objective responses were 
recorded in 31.7% (n = 38/120) in the nivolumab group vs. 10.6% of the investigators’ choice 
chemotherapy group (n = 5/47). Grade 3 and 4 drug-related serious events occurred in 5% 
(n = 12) of nivolumab-treated patients vs. 9% (n = 9). The grade 3 and 4 toxicities of nivolumab 
included deranged alanine aminotransferase, anaemia, and fatigue. There were no treatment-
related deaths in this group [39].
Pembrolizumab is another PD-1 inhibitor used in clinical practice. KEYNOTE-006, a mul-
ticentre phase 3 clinical trial, including 834 participants compared pembrolizumab vs. 
ipilimumab. They excluded participants who received prior checkpoint inhibitor therapy. 
The 6-month progression-free survival rates were 47.3% for pembrolizumab every 2 weeks, 
46.4% for pembrolizumab every 3 weeks, and 26.5% for ipilimumab. Twelve-month sur-
vival rates were 74.1, 68.4 and 58.2%, respectively. The response rate was higher with 
pembrolizumab, every 2-weeks (33.7%) and 3-weeks (32.9%) vs. ipilimumab (11.9%); 89.4, 
96.7 and 87.9% had a sustained response, with a median follow-up of 7.9 months. There 
was a reduced rate of treatment-related adverse effects of grade 3–5 severity in the pem-
brolizumab group (13.3 and 10.1%) vs. the ipilimumab group (19.9%). Thus, the efficacy 
in both pembrolizumab groups was significantly higher than ipilimumab, with reduced 
treatment-related adverse events [40]. Follow-up of KEYNOTE-006 in 2017 showed overall 
superiority and progression-free survival of pembrolizumab vs. ipilimumab. The median 
follow-up was 22.9 months. The 24-month overall survival rate was 55% in the 2-week 
group, 55% in the 3-week group, and 43% in the ipilimumab group. Most immune-related 
events occurred within the first 6 months of therapy. Colitis was more common in the ipi-
limumab group, whereas hepatitis and endocrinopathies were more common in the pem-
brolizumab group [41]. About 19% (n = 38) treated with pembrolizumab for at least a year 
developed grade 3–4 treatment-related adverse events. No patients died because of the 
therapy-related toxicity.
There is ongoing work investigating the role of atezolizumab in advanced melanoma. In 
a phase 1b trial, atezolizumab was combined with vemurafenib in BRAFV600 metastatic 
melanoma in 17 patients. It produced an overall response rate of 76%, with three complete 
responses and 10 partial responses. About 41% experienced grade 3 treatment-related adverse 
effect and no participants experienced a grade 4 adverse effect or death. Further work is nec-
essary to elucidate the role of atezolizumab in melanoma [42].
A recent analysis was performed on the safety data from 48 trials (n = 6938), including 26 
CTLA4, 17 PD-1, 2 PD-L1 trials and 3 CTLA4 and PD1. There were more grade 3/4 immune-
related adverse events with CTLA4 inhibitors vs. PD-1 (31% vs. 10%). Colitis, hypophysitis 
and rash were more common with CTLA4 inhibitors, whereas pneumonitis, hypothyroidism, 
arthralgia, and vitiligo were more common with PD1 inhibitors. Melanoma patients specifi-
cally have a higher incidence of gastrointestinal and skin immune-related adverse effects and 
a reduced incidence of pneumonitis. The discontinuation rate to immune-related adverse 
effects was between 3 and 12% in anti-PD-1 trials and 3 and 25% in anti-CTLA4 trials. The 
most frequent cause of discontinuation was diarrhoea/colitis. Death was an extremely uncom-
mon event for anti-PD1 agents (pembrolizumab 0.1%, nivolumab 0.3%) and mostly occurred 
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due to pneumonitis. Death occurred in 29 patients receiving CTLA-4 inhibitors and was more 
often due to gastrointestinal events such as diarrhoea, colitis, and colonic perforation [43].
3.1.3. IDO1-inhibitors
Indoleamine 2,3-dioxygenase (IDO-1) is a significant immunoregulatory enzyme that facili-
tates immunosuppression, tolerance, and tumour evasion by tryptophan catabolism [44]. It is 
a molecule which causes oxidative cleavage of tryptophan, an amino acid which is essential 
for cell proliferation and survival. IDO1 induction triggers dendritic cell apoptosis and inhib-
its T-cell response. In multiple cancer types, the IDO1 pathway is activated. In vitro, inhibi-
tion of IDO1 causes an increase in T and natural killer cells, increase in IFN-production, and 
reduced switch to regulatory T-cells [45].
Epacadostat is the first IDO-1 inhibitor in its class. Experimental evidence suggests that 
T-cells stimulated with dendritic cells treated with epacadostat produce a greater number 
of inflammatory mediators. Furthermore, there appears to be a decrease in the number of 
regulatory T cells [44]. Echo-202/KEYNOTE-037 was a phase 1 clinical trial, which enrolled 
62 patients with advanced melanoma. Patients treated previously with checkpoint inhibi-
tors were excluded. The patients received epacadostat plus pembrolizumab. Grade 3 or 
higher treatment-related adverse effects occurred in 18%, with the most common being 
rash, followed by increased lipase. No treatment-related deaths occurred. There were four 
complete responders, seven partial responders and three stable disease noted [46]. There 
were phase I/II trials with 40 advanced melanoma patients investigating the tolerability 
and efficacy of epacadostat plus ipilimumab. Grade 3 or higher immune-related treatment 
effects occurred in 23% of participants, rash, pruritus, diarrhoea, deranged transaminases, 
and hypothyroidism were the most commonly reported. Looking specifically at the immu-
notherapy-naive group, overall response rate was 27–30% (depending on the criteria used). 
The complete response in both criteria was 10% [47]. There are ongoing phase 3 studies 
(KEYNOTE-252/ECHO-301) investigating pembrolizumab and epacadostat in advanced 
melanoma. These trials will likely have a significant impact on the treatment algorithms for 
advanced melanoma.
3.1.4. Combination therapy
CTLA4 inhibitors and anti-PD1 inhibitors have been recently combined to determine if com-
bination therapy offers improved efficacy vs. monotherapy, with clinically acceptable safety 
outcomes. Checkmate 067 was a phase 3, multicentre trial which included patients with previ-
ously untreated stage III (unresectable)/IV melanoma with known BRAFV600 status. A total 
of 945 patients underwent randomisation to receive either nivolumab/ipilimumab or ipilim-
umab alone. All living patients had a minimum follow-up of 36 months, with a median follow-
up of 38 months. The overall survival rate at 3 years was 58% in the nivolumab/ipilimumab vs. 
34% in the ipilimumab group. Treatment-related adverse events of grade 3/4 were reported 
in 59% participants in the nivolumab/ipilimumab group, in 21% of the nivolumab group 
and 28% of the ipilimumab group. 32%, 46%, and 63% of patients received subsequent sys-
temic therapy in the nivolumab/ipilimumab, nivolumab and ipilimumab group,  respectively. 
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There were two deaths related to a study drug within 100 days and two deaths related to a 
study drug more than 100 days [48].
3.2. Autologous ex-vivo augmented tumour infiltrating lymphocytes
The immune response can be increased by either in vivo vaccination or proliferation of the 
antigen-specific effectors in vitro followed by transfer to the patient. The APCs used for gen-
erating effector responses are critical for determining the specificity and type of immune 
response. However, the response and essentially the outcome of the T-cells differ hugely 
whether it is in vivo or in vitro [49].
Adoptive cell therapy, unlike checkpoint inhibitors, creates an immune response, rather than 
simply “taking the breaks” off the immune system. It involves harvesting the T cells from 
the patient’s serum or tumour and then encouraging them to proliferate in a culture medium 
in vitro [25]. Adoptive cell therapy involves lymphodepletion prior to infusing autologous 
tumour infiltrating lymphocytes. In three clinical trials involving 93 patients with refractory 
melanoma, the response rate varied from 48 and 72%, depending on the chemoradiation strat-
egy employed for the lymphodepletion technique. The median follow-up varied between 10 
and 45 months for the trials. The 2-year survival rates ranged from 30 to 42%. There was 
one treatment-related death [50]. This treatment strategy only experimental and has not been 
approved by the US FDA for the treatment of melanoma.
3.3. Oncolytic viruses
An oncolytic virus is a non-pathogenic virus which destroys cancer cells, while leaving the 
normal cells unaffected [51]. The use of oncolytic viruses offers an attractive treatment strat-
egy. The oncolytic viruses result in cytotoxic effects by directly infecting the cancer cells. 
Furthermore, the viral genome can be manipulated to maximise the beneficial therapeutic 
effects and to minimise harmful effects. Oncolytic viruses involve the administration of either 
native or genetically modified viruses, which then enter the tumour cell selectively, prolifer-
ate and lyse these cells [52]. The endogenous defence mechanisms against viral-mediated 
infection are suboptimal in tumour cells. This results in a high turnover of the virus in the 
tumour cell. The cancer-specific replication is achieved by either selecting a non-virulent virus 
in humans or by manipulating the genome of the virus [53]. The viruses succeed in destroy-
ing the tumour cells through several mechanisms: primary lysis of the cancer cells, powerful 
bystander effects on healthy cells, provocation of local endogenous antiviral mechanisms and 
systemic antitumor immunity that can cause regression of the cancer at distant, uninfected 
cells. There are several types of oncolytic viruses developed: oncolytic poxvirus, oncolytic 
herpes simplex virus, oncolytic Coxsackie virus and oncolytic reovirus [52].
There are several barriers to treatment with oncolytic viruses: pathogenic potential, subopti-
mal ability to selectively target cancer cells, degradation by the immune system, and subopti-
mal ability to trigger T-cell response to neoplasm. Despite these limitations, the first oncolytic 
therapy known as laherparepvec was approved by the FDA for melanoma patients in 2015. It 
was indicated for patients with injectable lesions in the skin and lymph nodes that were not 
amenable to surgical resection [51].
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Laherparepvec is a genetically engineered oncolytic virus. It is a genetically modified HSV-1 
laherparepvec is used for the treatment of melanoma. It works in two different ways: it rep-
licates more actively in the tumour cells. This causes lysis of the tumour cells. Viral particles 
and tumour-associated antigens are released from the cells. The viral cells can preferentially 
target more tumour cells. The tumour antigen can induce an immune response, which is 
potentiated by the expression of GM-CSF in the laherparepvec. Laherparepvec functions by 
exploiting the protein kinase R (PKR) pathway. This pathway suppresses viral replication in 
healthy cells. The usual defence mechanism infected susceptible cell protein 34.5 is usually 
responsible for overcoming the PKR pathway in HSV. However, laherparepvec is genetically 
modified to delete the infected susceptible cell protein 34.5 in HSV-1, leaving the cells vulner-
able to degradation by PKR. In healthy cells, the PKR pathway is active and causes inactiva-
tion of the laherparepvec pathway. However, in the case of tumour cells, PKR is inactive. 
This leads to the virus actively replicating selectively in the tumour cells. Furthermore, there 
is a downregulation of type 1 IFN pathway in tumour cells. This leads to a further suscep-
tibility of tumour cells to laherparepvec [54]. The OPTiM trial randomised patients to either 
intralesional laherparepvec or subcutaneous GM-CSF in patients with stage 3 and 4 melano-
mas. The trial showed monotherapy with laherparepvec significantly increases the durable 
response rate vs. therapy with GM-CSF alone (25.2% vs. 1.2%, respectively). It also improved 
the overall response rate (40.5% vs. 2.3%, respectively). The toxicity profile was similar in both 
treatment arms, with the majority of toxicities including grade 1 and 2 toxicities [55]. There 
are ongoing phase 3 trials examining the efficacy of combination therapy with laherparepvec 
and pembrolizumab in stage 3 and 4 melanomas. Earlier phase 2 trials appear promising.
3.4. Dendritic cells
Dendritic cells are a form of immune cell, which is the more powerful antigen-presenting cell. 
The cells circulate in their inactive state in the body circulation. When they are exposed to a dan-
ger signal, they become activated antigen-presenting cells. They facilitate immune responses in 
the lymphoid tissue, causing the naïve T-cells to differentiate into effector T cells. DC cells facil-
itate activation of tumour immunity. They activate antigen-specific T cell responses in mela-
noma patients. Dendritic cell vaccines are activated dendritic cells containing tumour antigens. 
Dendritic cells are not advisable as monotherapy in the treatment of advanced melanoma. 
However, there are promising results when DC viruses are combined with ipilimumab. It is 
postulated that the immune system is more potent in stage 3 vs. stage 4 melanoma. Dendritic 
cells show some promise in stage III melanoma. However, phase 3 trials are pending. The 
safety profile of DC vaccines is favourable when compared with checkpoint inhibitors [56].
4. Chemotherapy
In the advent of targeted therapies, chemotherapy is no longer deemed a first-line therapy for 
metastatic cutaneous melanoma in the latest ESMO guidelines [2]. However, in the recent past, 
chemotherapy was an important therapeutic strategy for palliation. Examples of chemothera-
peutic agents employed in melanoma include dacarbazine, temozolomide, nab-paclitaxel, pacli-
taxel, cisplatin, carboplatin, and vinblastine. The only chemotherapy agent approved by the FDA 
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is dacarbazine. Dacarbazine and temozolomide (an analogue drug) are alkylating agents that 
damage DNA, leading to cell apoptosis. Multiple phase 3 studies have failed to demonstrate an 
overall survival benefit for any chemotherapy regimen. Specifically, only 10–20% will respond 
to dacarbazine. The progression-free rate is 3–6 months with dacarbazine. The adverse effects of 
dacarbazine include bone marrow suppression and nausea/vomiting. Former combination regi-
ments included BOLD (bleomycin, vincristine, lomustine and dacarbazine), CVD (cisplatin, vin-
blastine and dacarbazine) and the Dartmouth regimen (dacarbazine, cisplatin, carmustine and 
tamoxifen). However, the studies failed to demonstrate a benefit to combination chemotherapy 
vs. monotherapy. Furthermore, the toxicity profiles of the combination therapy were worse than 
monotherapy. Combining immunotherapy and chemotherapy similarly failed to demonstrate 
any significant benefit. It also led to worse outcomes in terms of toxicity profiles [57].
5. Conclusion
In conclusion, immunotherapy and targeted therapy in the form of BRAF/MEPK inhibitors 
form the backbone of therapy for metastatic melanoma. The optimal agents remain under 
considerable debate. Chemotherapy has been relegated to second-line therapy. Future guide-
lines will likely reflect this new research.
In conclusion, the mainstay treatment for managing melanoma remains surgery if feasible. 
There are several adjuvant therapies such as anti-PD1 therapies, CTLA4 inhibitors and BRAF/
MEK inhibitors that may play a useful role as adjuvant therapies in high-risk, stage 3 dis-
ease. The treatment strategies for advanced melanoma are evolving rapidly. Targeted thera-
pies such as anti-PD1 therapies, CTLA4 inhibitors and BRAF/MEK inhibitors have become 
mainstay treatment. Further research must be carried out to determine the best regimen. 
Chemotherapy now only plays a role in rescue therapy.
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